{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:34Z","timestamp":1789614154806,"version":"build-2803163510"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Statistics"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Dose\u2010escalation trials make sequential dosing decisions for cohorts of patients based on accumulating toxicity data, often in the form of dose\u2010limiting toxicities (DLTs). Challenges arise due to the necessity of complete follow\u2010up for accurate dosing decisions. There are many settings where patients may become available to be enrolled before there is complete DLT information from the patients already in the trial. In radiotherapy trials, for example, the DLT assessment window is far longer than traditional chemotherapies and waiting for complete DLT information can result in impractically long trial durations. This issue can be exacerbated in escalation trials of dose\u2010combinations, where the space to be explored and the sample sizes are generally larger. The time\u2010to\u2010event (TITE) approach, which utilizes partial follow\u2010up data, has been effective in reducing trial lengths while ensuring accuracy and safety. Whether TITE methods are beneficial depends critically on the relationship between the DLT assessment window length and patient inter\u2010arrival time, characterized by the assessment\u2010to\u2010interarrival (A\/I) ratio. However, the impact of the rate of accrual into the trial and the size of each dosing cohort have not been carefully considered because it is widely assumed that accrual rates will be slow and the A\/I ratio will be small. We use comprehensive simulation studies based on a dose\u2010combination case\u2010study and show that accrual rates corresponding to larger A\/I ratios can result in poor accuracy and safety, while a dosing cohort size of one can additionally induce unfavorable operating characteristics. To address this issue, we propose a modification to the TITE design where the trial is paused if there are a certain number of non\u2010completers. We demonstrate that this simple modified approach is robust across the range of A\/I ratios investigated and has non\u2010inferior operating characteristics to a non\u2010TITE design while providing meaningful reductions in trial duration.<\/jats:p>","DOI":"10.1002\/pst.70119","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:57:55Z","timestamp":1789437475000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Enrollment Strategies on the Performance of Time\u2010To\u2010Event Dose\u2010Escalation Designs for Phase I Drug Combination Oncology Trials"],"prefix":"10.1002","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5665-8004","authenticated-orcid":false,"given":"Xiaowen","family":"Tian","sequence":"first","affiliation":[{"name":"Oncology Biometrics, Oncology R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-8965","authenticated-orcid":false,"given":"Michael","family":"Sweeting","sequence":"additional","affiliation":[{"name":"Oncology Biometrics, Oncology R&amp;D AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-3702","authenticated-orcid":false,"given":"Kristine","family":"Broglio","sequence":"additional","affiliation":[{"name":"Oncology Biometrics, Oncology R&amp;D AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0295"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.02.009"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4087"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30096-2"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2466"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae165.0461"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.01177.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-01012-z"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12323"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1621"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1214\/13-BA839"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5491"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxm044"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4255"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990530)18:10<1155::AID-SIM114>3.0.CO;2-H"},{"key":"e_1_2_10_18_1","unstructured":"Food and Drug Administration \u201cOptimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseasesguidance for Industry \u201d 2024."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-1658"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-4198"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2015.10.018"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1198\/tast.2009.0030"}],"container-title":["Pharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.70119","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pst.70119","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.70119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:29:22Z","timestamp":1789612162000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pst.70119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/pst.70119"],"URL":"https:\/\/doi.org\/10.1002\/pst.70119","archive":["Portico"],"relation":{},"ISSN":["1539-1604","1539-1612"],"issn-type":[{"value":"1539-1604","type":"print"},{"value":"1539-1612","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70119"}}